Clinical Trial Update: Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over [Phase 1, Phase 2]

View source ↗

Summary

This document outlines an ongoing Phase 1/2 clinical trial evaluating the safety and immunogenicity of an investigational herpes zoster vaccine, Z-1018, in adul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)
• Z-1018

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: Shingles, Herpes Zoster | Phase 1, Phase 2 | Status: RECRUITING